Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PRRT3 antisense RNA 1 (PRRT3-AS1) is a long non-coding RNA (lncRNA) gene located on chromosome 15 that does not code for a protein but is implicated in the regulation of gene expression, especially in cancer contexts[1][5]. It is upregulated in various human cancers, including non-small cell lung cancer (NSCLC) and prostate cancer[2][3]. Functionally, PRRT3-AS1 acts as a competing endogenous RNA (ceRNA), chiefly by sponging microRNA-507 (miR-507), thereby derepressing target genes such as HOXB5[2][3]. Its overexpression promotes malignant behaviors such as enhanced proliferation, migration, and invasion of cancer cells, whereas its depletion suppresses these phenotypes both in vitro and in vivo[2][3]. Due to these characteristics, PRRT3-AS1 is being investigated as a potential diagnostic, prognostic, and therapeutic target in cancers, but no direct interacting drugs or established safety concerns have been reported to date. The full spectrum of its molecular mechanisms is still under investigation[1][2][3].
Post-transcriptional regulation via miRNA sponging (primarily miR-507), Regulation of the HOXB5 axis downstream of miR-507
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PRRT3 antisense RNA 1 (PRRT3-AS1).